A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma (AQUA)

Genentech

Status and phase: Completed; Phase 2

Conditions: Allergic Asthma

Treatments: Drug: placebo; Drug: omalizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00434434

Q4160g

Details and patient eligibility

About

This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult subjects with mild allergic asthma.

Enrollment: 61 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed Informed Consent Form
• Meet criteria for the diagnosis of allergic asthma
• Be between the ages of 18 to 65 years
• Have a normal chest X-ray within 2 years of screening

Exclusion criteria

• Need daily controller medication for asthma
• History of hypersensitivity to the study drug or to drugs with similar chemical structures or to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin)
• Have a documented medical history of anaphylaxis
• Have lung disease other than mild allergic asthma
• Have taken other investigational drugs within 30 days or 5 half-lives prior to the screening visit, whichever is longer
• Are unable or unwilling to comply with study procedures and visits
• Are pregnant or lactating
• Have significant medical illness other than asthma, including malignancies, parasitic infections, immune system disorders, and thrombocytopenia
• Have been treated with omalizumab within 12 months prior to screening
• Currently smoke or have a history of smoking more than 10 pack-years
• Have a history of drug or alcohol abuse, which, in the judgment of the investigator, may put the subject at risk for being unable to participate fully in the study for the duration of the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

61 participants in 3 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: omalizumab

Drug: omalizumab

2

Experimental group

Treatment:

Drug: omalizumab

Drug: omalizumab

3

Placebo Comparator group

Treatment:

Drug: placebo